BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 958 | Download: 665
Publication Name World Journal of Clinical Oncology
Manuscript ID 8433
Country United States
Received
2013-12-28 14:01
Peer-Review Started
2013-12-28 18:14
To Make the First Decision
2014-02-13 16:22
Return for Revision
2014-04-18 08:44
Revised
2014-03-04 12:29
Second Decision
2014-04-19 14:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-04-19 14:35
Articles in Press
2014-05-23 09:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-05-08 19:13
Typeset the Manuscript
2014-07-18 10:11
Publish the Manuscript Online
2014-08-01 15:17
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions
Manuscript Source Invited Manuscript
All Author List Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr and Matias E Valsecchi
Funding Agency and Grant Number
Corresponding Author Matias E Valsecchi, MD, MS, Medical Oncology, HIMG, 5170 US Route 60 East, Huntington, WV 25705, United States. meval78@yahoo.com
Key Words Breast cancer; Human epidermal growth factor receptor-2; Trastuzumab; Pertuzumab; Ado-trastuzumab; Lapatinib
Core Tip This is a review manuscript with the most updated information regarding the state of the art management of human epidermal growth factor receptor-2 positive breast cancer. It summarizes the most relevant and updated information derived from more than 40 phase Ⅱ and Ⅲ clinical trials that constitute the theoretical framework to support our daily practice. It also highlights some key clinical concepts that should not be overlooked by critically appraising the current literature. Finally, it gives the reader with a compilation of potential new agents that are currently being tested and may soon become the next step in the battle against this disease.
Publish Date 2014-08-01 15:17
Citation Recondo G Jr, Dìaz Canton E, de la Vega M, Greco M, Recondo G Sr, Valsecchi ME. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol 2014; 5(3): 440-454
URL http://www.wjgnet.com/2218-4333/full/v5/i3/440.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i3.440
Full Article (PDF) WJCO-5-440.pdf
Full Article (Word) WJCO-5-440.doc
Manuscript File 8433-Review.doc
Answering Reviewers 8433-Answering reviewers.pdf
Copyright License Agreement 8433-Copyright assignment.pdf
Peer-review Report 8433-Peer review(s).pdf
Scientific Editor Work List 8433-Scientific editor work list.doc